logo

The NeoKidney: Next Generation Hemodialysis Device Making Hemodialysis Finally Portable

Sector: Residential • Location: Netherlands

Source: EU Funding & Tenders Portal

Project
Ongoing

NextKidney BV, founded in 2014 and based in Netherlands, is revolutionizing kidney care with NeoKidney, a compact, truly portable home hemodialysis (HHD) device. With over 5 million end-stage renal disease (ESRD) patients worldwide, most rely on costly, in-clinic dialysis, which limits mobility, increases fatigue, and has sub-optimal health outcomes. HHD offers benefits over in-clinic dialysis, bu

Project Information FAQ

Project Information

3 Q
The project “The NeoKidney: Next Generation Hemodialysis Device Making Hemodialysis Finally Portable” is an infrastructure initiative in the Residential sector, located in Netherlands. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ongoing

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

NextKidney BV, founded in 2014 and based in Netherlands, is revolutionizing kidney care with NeoKidney, a compact, truly portable home hemodialysis (HHD) device. With over 5 million end-stage renal disease (ESRD) patients worldwide, most rely on costly, in-clinic dialysis, which limits mobility, increases fatigue, and has sub-optimal health outcomes. HHD offers benefits over in-clinic dialysis, but adoption remains below 2% due to current devices being bulky and challenging to set up. NeoKidney addresses these barriers by offering a 10 kg portable device that uses patented sorbent technology to recycle dialysate, reducing fluid needs from 45 to 5 liters per session. Its innovative cardiac floating technology also eliminates the need for electrical grounding, enabling use in various settings, including remote and disaster zones. Together, these features make NeoKidney more easily accessible to patients. NeoKidney’s benefits include 40% reduction in mortality, greater patient independence, and healthcare cost savings of up to 43% per patient annually (from €92K to €53K). Integrated remote monitoring allows healthcare providers to track patient data in real time, reducing need for hospital visits. With global dialysis market valued at €82 billion in 2022, and HHD segment expected to grow to €7 billion by 2035, NeoKidney aims to capture significant market share, with projected sales of €650M annually by 2035. NextKidney's commercialization strategy includes selling both the NeoKidney device and high-margin consumables, with initial market entry in Europe and the U.S. NextKidney seeks €41.5M in funding, including €2.5M in EIC grants and €39M in equity (€15M from EICA and €24M from current and additional investors), to accelerate clinical trials, regulatory approval, and market penetration. This funding is critical for maintaining NextKidney’s first-mover advantage, ensuring the rapid rollout of this life-changing technology for home hemodialysis patients.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data